An Alzheimer's vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said.
Researchers at the Massachusetts Institute of Technology (MIT) have developed a machine-learning model they say can predict whether people at risk for Alzheimer’s disease will experience clinically significant cognitive decline within the next 2 years.
A test that measures levels of amyloid beta in the blood, when factored with a person’s age and the presence of the genetic variant APOE4, can identify brain changes from early Alzheimer’s disease with 94% accuracy, according to a study published online in Neurology.
Biogen Inc and partner Eisai Co Ltd said they would abandon two late-stage trials testing experimental Alzheimer's treatment elenbecestat, months after scrapping trials of another drug for the memory-robbing disease.
Drugmaker Eli Lilly said on Thursday early results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms.